Comparative Pharmacology
Head-to-head clinical analysis: DUREZOL versus INFLAMASE MILD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUREZOL versus INFLAMASE MILD.
DUREZOL vs INFLAMASE MILD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene synthesis, and suppressing immune cell migration and cytokine release.
Inflammase Mild is a combination product containing hydrocortisone, a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis. It also contains benzalkonium chloride, a quaternary ammonium compound with antiseptic properties.
1 drop of 0.1% ophthalmic solution in the affected eye(s) four times daily for up to 14 days.
N/A
None Documented
None Documented
Terminal elimination half-life is 12–18 hours in adults; prolonged to 24–36 hours in hepatic impairment.
1.5-2.5 hours; short half-life allows frequent dosing for mild inflammation.
Renal excretion of unchanged drug accounts for 30% of clearance; biliary/fecal elimination accounts for 60%, with the remainder as metabolites.
Renal excretion of unchanged drug (approximately 60%) and glucuronide conjugate (20%); biliary/fecal (15%).
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid